Amer Zeidan, Professor of Medicine and Chief of Hematologic Malignancies at Yale Cancer Center, shared on LinkedIn:
“Extremely humbled and proud to receive the 2026 King Hussein Cancer Research Lifetime Achievement Award (international track) by the King Hussein Cancer Foundation and Center and presented by HRH Prince Talal and Princess Ghida Talal.
It is extra special since it is the 25th anniversary for KHCC where I worked in 2003 before moving to USA.”
About Amer Zeidan
Amer Zeidan is a Professor of Medicine at Yale School of Medicine and Chief of Hematologic Malignancies at Yale Cancer Center. He specializes in blood cancers, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
His research focuses on improving treatment options for patients with blood cancers, with particular emphasis on developing new therapies and advancing clinical trials. He has authored more than 330 scientific publications and has played an active role in international efforts to improve the diagnosis and treatment of MDS.
In 2026, Zeidan received the King Hussein Cancer Research Lifetime Achievement Award (International Track) in recognition of his contributions to hematology and cancer research, particularly his work advancing the understanding and treatment of blood cancers. The award was especially meaningful as he began his career at King Hussein Cancer Center in Jordan in 2003, before moving to the United States.
You may also be interested in:
